Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium–glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationTafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationGroenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1858 · Cited by 2,043
Irbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationBozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2115 · Cited by 1,665
Self-citationMyocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Self-citationObokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01429-5 · Cited by 996
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Chioncel, O., Lainscak, M., Seferovic, P. M., Anker, S. D., Crespo-Leiro, M. G., Harjola, V.-P., Parissis, J., Laroche, C., Piepoli, M. F., Fonseca, C., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.813 · Cited by 927
Self-citationMohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., & Redfield, M. M. (2015) · Circulation · doi:10.1161/circulationaha.114.009625 · Cited by 874
Heart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
Self-citationShah, S. J., Lam, C. S. P., Svedlund, S., Saraste, A., Hage, C., Tan, R.-S., Beussink-Nelson, L., Ljung Faxén, U., Fermer, M. L., Broberg, M. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy531 · Cited by 656
NADPH Oxidases in Cardiovascular Health and Disease
Cave, A. C., Brewer, A. C., Narayanapanicker, A., Ray, R., Grieve, D. J., Walker, S., & Shah, A. M. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.691 · Cited by 630
Cardiac Steatosis in Diabetes Mellitus: A 1 H-Magnetic Resonance Spectroscopy Study
McGavock, J. M., Lingvay, I., Zib, I., Tillery, T., Salas, N., Unger, R., Levine, B. D., Raskin, P., Victor, R. G., & Szczepaniak, L. S. (2007) · Circulation · doi:10.1161/circulationaha.106.645614 · Cited by 612
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Solomon, S. D., Vaduganathan, M., L. Claggett, B., Packer, M., Zile, M., Swedberg, K., Rouleau, J., A. Pfeffer, M., Desai, A., H. Lund, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044586 · Cited by 551
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction
Cohen, J. B., Schrauben, S. J., Zhao, L., Basso, M. D., Cvijic, M. E., Li, Z., Yarde, M., Wang, Z., Bhattacharya, P. T., Chirinos, D. A., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.009 · Cited by 432
Relationship between physical activity, body mass index, and risk of heart failure
Pandey, A., LaMonte, M., Klein, L., Ayers, C., Psaty, B. M., Eaton, C. B., Allen, N. B., de Lemos, J. A., Carnethon, M., Greenland, P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.081 · Cited by 398
Thomopoulos, C., Parati, G., & Zanchetti, A. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000378 · Cited by 388
Mueller, S., Winzer, E. B., Duvinage, A., Gevaert, A. B., Edelmann, F., Haller, B., Pieske-Kraigher, E., Beckers, P., Bobenko, A., Hommel, J., et al. (2021) · JAMA · doi:10.1001/jama.2020.26812 · Cited by 347
Self-citationHeart Failure With Preserved Ejection Fraction and Diabetes
McHugh, K., DeVore, A. D., Wu, J., Matsouaka, R. A., Fonarow, G. C., Heidenreich, P. A., Yancy, C. W., Green, J. B., Altman, N., & Hernandez, A. F. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.033 · Cited by 313
Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057983 · Cited by 299
Self-citationButler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab798 · Cited by 264
Self-citationResting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease
Böhm, M., Reil, J.-C., Deedwania, P., Kim, J. B., & Borer, J. S. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.09.016 · Cited by 236
Self-citationKristensen, S. L., Mogensen, U. M., Jhund, P. S., Petrie, M. C., Preiss, D., Win, S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024593 · Cited by 202
Dayan, V., Vignolo, G., Magne, J., Clavel, M.-A., Mohty, D., & Pibarot, P. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.076 · Cited by 201
Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., Heidenreich, P. A., & Fonarow, G. C. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.025 · Cited by 160
Reddy, Y. N. V., Lewis, G. D., Shah, S. J., Obokata, M., Abou-Ezzedine, O. F., Fudim, M., Sun, J.-L., Chakraborty, H., McNulty, S., LeWinter, M. M., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.11.037 · Cited by 141
Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059785 · Cited by 131
Self-citationBeldhuis, I. E., Streng, K. W., Ter Maaten, J. M., Voors, A. A., van der Meer, P., Rossignol, P., McMurray, J. J. V., & Damman, K. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003588 · Cited by 126
Beale, A. L., Warren, J. L., Roberts, N., Meyer, P., Townsend, N. P., & Kaye, D. (2019) · Open Heart · doi:10.1136/openhrt-2019-001012 · Cited by 112
Prevalence and clinical significance of diabetes in asian versus white patients with heart failure
Bank, I. E. M., Gijsberts, C. M., Teng, T.-H. K., Benson, L., Sim, D., Yeo, P. S. D., Ong, H. Y., Jaufeerally, F., Leong, G. K. T., Ling, L. H., et al. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2016.09.015 · Cited by 87
Self-citationCHARM Investigators and Committees, Kristensen, S. L., Jhund, P. S., Lee, M. M. Y., Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6754-x · Cited by 83
Guo, Y., Xiao, C., Zhao, K., He, Z., Liu, S., Wu, X., Shi, S., Chen, Z., & Shi, R. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001254 · Cited by 16
Metadata
- Authors
- Anker, S. D., Usman, M. S., Anker, M. S., Butler, J., Böhm, M., Abraham, W. T., Adamo, M., Chopra, V. K., Cicoira, M., Cosentino, F., Filippatos, G., Jankowska, E. A., Lund, L. H., Moura, B., Mullens, W., Pieske, B., Ponikowski, P., Gonzalez-Juanatey, J. R., Rakisheva, A., Savarese, G., Seferovic, P., Teerlink, J. R., Tschöpe, C., Volterrani, M., von Haehling, S., Zhang, J., Zhang, Y., Bauersachs, J., Landmesser, U., Zieroth, S., Tsioufis, K., Bayes-Genis, A., Chioncel, O., Andreotti, F., Agabiti-Rosei, E., Merino, J. L., Metra, M., Coats, A. J. S., & Rosano, G. M. C.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-01
- Volume
- 25
- Issue
- 7
- Pages
- 936-955
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W4377099139
- Cited by
- 201
- References
- 56
- FWCI
- 35.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.